CAR T Cells With Dual Targeting of CD19 and CD22 in Adult Patients With Recurrent or Refractory B Cell Malignancies: A Phase 1 Trial

Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells experience progressive disease. To prevent relapse, investigators tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and large B cell lymphoma (LBCL), and demonstrated the feasibility of manufacturing in a closed system, safety of bispecific CAR T cells, and clinical activity in both B-ALL and LBCL.